ClinicalTrials.gg
RecruitingNCT07751172Updated Oct 22, 2026

Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter

An interventional study of Lens A (paflufocon D) in Myopia and Astigmatism, sponsored by CooperVision International Limited (CVIL). Recruiting at 3 sites in 2 countries. Open to participants aged 7 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
7 Years to 35 Years
Sex
All
01

Study summary

To evaluate the clinical performance and user-reported experience of Paragon CRT contact lenses with a 5mm Optic Zone Diameter (OZD)

Read the detailed description

Prospective, multi-site, clinical study evaluating the first-fit success, visual performance, and ocular health outcomes of 5mm OZD orthokeratology lenses fit empirically.

02

Conditions studied

  • Myopia
  • Astigmatism
03

In context

Myopia

1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.

This study's planned enrollment of 70 is below the median of 78 across 923 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

CooperVision International Limited (CVIL) is the lead sponsor of 138 studies on the registry; 6 are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 66 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A person is eligible for inclusion in the study if they:

  1. Are 6- 35 years of age
  2. If under 18 years old they are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document
  3. Have had a self-reported visual exam in the last two years
  4. Are able to read (or be read to), understand and sign the assent document if under 18 years old or are able to read, understand and sign the consent document if aged 18 or older
  5. Are willing to comply with the wear schedule (approximately 8 hours per night for every night, while sleeping)
  6. Are willing to comply with the visit schedule
  7. Have a refractive spherical component of their prescription between -0.50 and up to -6.00 diopters (inclusive) AND a refractive cylinder of no more than -1.75 diopters
  8. Have a refractive spherical component ≥ cylinder component
  9. Have a minimum visual acuity of +0.20 logMAR with each eye, when refracted at the Screening visit
  10. Have clear corneas and no active ocular disease.
  11. Have no medication, medical condition, or ocular conditions that contraindicate contact lens wear OR are expected to affect lens comfort or vision across the 1-month study duration, in the opinion of the investigator
  12. Can be shown to have stable keratometry for at least the previous 1 month, if they have previously worn orthokeratology lenses.

Exclusion criteria

Exclusion Criteria:

  1. Present at screening visit with the presence of ocular or systemic disease or report the use medications which might interfere with orthokeratology contact lens wear, such as keratoconus, diabetes mellitus, eye drops
  2. Have a post-treatment predicted flat K value ≤38.00D (e.g. Patient baseline flat keratometry value = 40.00, patient has 2.00D of myopic refractive error. 40.00-2.00= 38.00D)
  3. Have a known sensitivity to the diagnostic sodium fluorescein to be used in the study
  4. Are pregnant, planning a pregnancy or lactating
  5. Have amblyopia
  6. Have presbyopia or has dependence on spectacles for near work over the contact lenses
  7. Present at screening visit with the presence of (grade ≥3; ISO scale) anterior segment abnormalities.
  8. Present at screening visit with slit lamp findings that would contraindicate orthokeratology contact lens wear such as:

1. Pathological dry eye or associated findings 2. Pterygium, pinguecula, or corneal scars within the visual axis 3. Neovascularization > 0.75 mm from of the limbus 4. Giant papillary conjunctivitis (GPC) worse than grade 1 5. Anterior uveitis or iritis (past or present) 6. Seborrheic eczema, Seborrheic conjunctivitis 7. History of corneal ulcers or fungal infections 8. Poor personal hygiene 9. Aphakia

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Other
    Paragon CRT Orthokeratology contact lens

    Device: Lens A (paflufocon D)

Interventions

  • DeviceLens A (paflufocon D)

    5 minutes of daily wear

06

What researchers measure

Primary outcomes

  1. Comfort at 5 Minutes and 1 Month After Final Lens Dispense

    To assess participant-reported comfort of empirically fitted orthokeratology contact lenses by comparing comfort scores measured 5 minutes after lens insertion at the final dispense visit with comfort scores reported after 1 month of lens wear. Comfort will be assessed using a 0 to 10 scale, where 0 indicates "painful" and 10 indicates "cannot feel the lenses

    Time frame: 5 minutes after insertion

07

Study locations

2 of 3 sites recruiting
  • Treehouse Eyes Pleasanton Center
    Pleasanton, California 94588, United States
    Recruiting
  • Bellaire Family Eye Care
    Bellaire, Texas 77401, United States
    Recruiting
    • Sarah Maldonado · ContactSarah@BFEYE.COM · 7136648087
    • Ashley Tucker, OD · Principal investigator
  • Complutense University of Madrid Av.
    Madrid, Moncloa - Aravaca, 28040, Spain
    Not yet recruiting
    • Juan Gonzalo Carracedo Rodriguez, PhD · Contactjgcarrac@ucm.es · +34616513539
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 4 months is below that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 7, 2026
StartActual
Aug 14, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
Show 3 sites
  • Treehouse Eyes Pleasanton Center · Pleasanton, United Statesno status→Recruiting
  • Bellaire Family Eye Care · Bellaire, United Statesno status→Recruiting
  • Complutense University of Madrid Av. · Madrid, Spainno status→Not yet recruiting
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
    Show 3 sites
    • Treehouse Eyes Pleasanton Center · Pleasanton, United Statesno status→Recruiting
    • Bellaire Family Eye Care · Bellaire, United Statesno status→Recruiting
    • Complutense University of Madrid Av. · Madrid, Spainno status→Not yet recruiting
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07751172
Collaborators
CooperVision, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Aug 14, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 22, 2026

Study contacts

Kelly Voltz
Contact
KVoltz@coopervision.com
+19256604364

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion